CN103118684A - 用于治疗睾酮缺乏的睾酮溶液 - Google Patents

用于治疗睾酮缺乏的睾酮溶液 Download PDF

Info

Publication number
CN103118684A
CN103118684A CN2011800396639A CN201180039663A CN103118684A CN 103118684 A CN103118684 A CN 103118684A CN 2011800396639 A CN2011800396639 A CN 2011800396639A CN 201180039663 A CN201180039663 A CN 201180039663A CN 103118684 A CN103118684 A CN 103118684A
Authority
CN
China
Prior art keywords
testosterone
solution
administered
levels
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800396639A
Other languages
English (en)
Chinese (zh)
Inventor
F·W·H·M·马库斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INNOTESTO bvba
Original Assignee
INNOTESTO bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INNOTESTO bvba filed Critical INNOTESTO bvba
Publication of CN103118684A publication Critical patent/CN103118684A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2011800396639A 2010-08-16 2011-08-09 用于治疗睾酮缺乏的睾酮溶液 Pending CN103118684A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1013701.6 2010-08-16
GB1013701.6A GB2482868A (en) 2010-08-16 2010-08-16 A testosterone liquid spray formulation for oromucosal administration
PCT/EP2011/004031 WO2012022446A1 (en) 2010-08-16 2011-08-09 Testosterone solutions for the treatment of testosterone deficiency

Publications (1)

Publication Number Publication Date
CN103118684A true CN103118684A (zh) 2013-05-22

Family

ID=42938015

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800396639A Pending CN103118684A (zh) 2010-08-16 2011-08-09 用于治疗睾酮缺乏的睾酮溶液

Country Status (12)

Country Link
US (1) US9498436B2 (enExample)
EP (1) EP2605778B1 (enExample)
JP (1) JP5816690B2 (enExample)
CN (1) CN103118684A (enExample)
AU (1) AU2011291075B2 (enExample)
BR (1) BR112013003471A2 (enExample)
CA (1) CA2807405A1 (enExample)
DK (1) DK2605778T3 (enExample)
ES (1) ES2539582T3 (enExample)
GB (1) GB2482868A (enExample)
WO (1) WO2012022446A1 (enExample)
ZA (1) ZA201300858B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019161707A1 (zh) * 2018-02-24 2019-08-29 中山大学 一种猴睾酮缺乏模型的建立方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010038259B4 (de) 2010-10-19 2013-02-07 4Jet Sales + Service Gmbh Verfahren und Vorrichtung zum Gravieren eines flexiblen Bands
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
WO2014083432A2 (en) * 2012-11-14 2014-06-05 Trimel Biopharma Srl Female intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
ITUB20161027A1 (it) 2016-02-24 2017-08-24 Altergon Sa Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio
MX2020008147A (es) 2018-02-02 2020-10-28 Acerus Biopharma Inc Metodos de terapia de testosterona.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1323198A (zh) * 1998-10-14 2001-11-21 阿迪尔公司 包含性激素和环糊精的鼻用喷雾溶液的制备方法
EP1872774A1 (en) * 2006-06-07 2008-01-02 Familplan Consulting Ltd Oy A pharmaceutical composition adapted for oral transmucosal administration comprising sex hormone and its use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
EP0381747A4 (en) * 1988-08-15 1991-09-11 American Maize-Products Company Water soluble branched beta cyclodextrin steroid complex
US5955098A (en) * 1996-04-12 1999-09-21 Flemington Pharmaceutical Corp. Buccal non polar spray or capsule
ATE288255T1 (de) 1996-04-12 2005-02-15 Novadel Pharma Inc Polares bukkales spray
US20050180923A1 (en) * 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20030027804A1 (en) * 2001-06-27 2003-02-06 Van Der Hoop Roland Gerritsen Therapeutic combinations for the treatment of hormone deficiencies
JP4740589B2 (ja) * 2002-04-29 2011-08-03 グラクソ グループ リミテッド 警告システム
PL1670433T3 (pl) * 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
ES2258694T3 (es) 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1323198A (zh) * 1998-10-14 2001-11-21 阿迪尔公司 包含性激素和环糊精的鼻用喷雾溶液的制备方法
EP1872774A1 (en) * 2006-06-07 2008-01-02 Familplan Consulting Ltd Oy A pharmaceutical composition adapted for oral transmucosal administration comprising sex hormone and its use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019161707A1 (zh) * 2018-02-24 2019-08-29 中山大学 一种猴睾酮缺乏模型的建立方法

Also Published As

Publication number Publication date
BR112013003471A2 (pt) 2019-09-24
WO2012022446A1 (en) 2012-02-23
AU2011291075A1 (en) 2013-03-28
ZA201300858B (en) 2015-09-30
EP2605778A1 (en) 2013-06-26
ES2539582T3 (es) 2015-07-02
GB201013701D0 (en) 2010-09-29
JP2013534228A (ja) 2013-09-02
EP2605778B1 (en) 2015-03-25
DK2605778T3 (en) 2015-06-15
US20130143851A1 (en) 2013-06-06
US9498436B2 (en) 2016-11-22
AU2011291075B2 (en) 2015-02-05
JP5816690B2 (ja) 2015-11-18
GB2482868A (en) 2012-02-22
CA2807405A1 (en) 2012-02-23

Similar Documents

Publication Publication Date Title
CN103118684A (zh) 用于治疗睾酮缺乏的睾酮溶液
EP2800571B1 (en) Oromucosal liquid estradiol compositions
CN1607950B (zh) 用于口腔施用的包含烟碱的液体药物制剂
JP4825305B2 (ja) 経皮吸収製剤
US9186320B2 (en) Controlled release delivery system for nasal application of neurotransmitters
ES2641613T3 (es) Gel transdérmico de Nestorone®/Estradiol
US20030087885A1 (en) Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
HK1225311A1 (zh) 透皮或透粘膜应用活性剂的用途和制剂
WO2009080023A1 (en) Compressed chewing gum comprising peptide
IL215944A (en) Use of a testosterone-containing preparation for the treatment of a testosterone deficiency
JP2004506698A (ja) ヒトに用いるためのテストステロンエステル製剤
TW201717932A (zh) 雙醋瑞因或瑞因外用製劑及其用途
US20050059615A1 (en) Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
WO2009101412A1 (en) Topical pharmaceutical composition
US20170128462A1 (en) Methods for treating female sexual dysfunction while decreasing cardiovascular risk
JP2008539236A (ja) 乾癬を治療するためのクロベタゾールスプレー製剤の使用
Leichtnam et al. Testosterone hormone replacement therapy: state-of-the-art and emerging technologies
CA2604077A1 (en) Method of treating or preventing type-2 diabetes
JP2025160345A (ja) 薬学的組成物
CN120641106A (zh) 局部药物组合物和其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130522